MeiraGTx (MGTX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual General Meeting scheduled for June 12, 2025, with voting open until June 11, 2025, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 29, 2025.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of Thomas E. Shenk, Ph.D., as director is on the ballot.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board recommends voting in favor of both proposals.
Additional business may be transacted as appropriate during the meeting.
Board of directors and corporate governance
Board has nominated Thomas E. Shenk, Ph.D., for election as director at the upcoming meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MeiraGTx
- Director elections, auditor ratification, and robust governance highlight this year's proxy.MGTX
Proxy filing30 Apr 2026 - Director elections and auditor ratification headline the June 2026 annual meeting agenda.MGTX
Proxy filing30 Apr 2026 - AAV-AQP1/AAV-hAQP1 delivers durable, transformative benefit for persistent xerostomia.MGTX
KOL event16 Apr 2026 - Pivotal gene therapy programs and Riboswitch platform drive late-stage pipeline and market growth.MGTX
Corporate presentation16 Apr 2026 - Breakthrough designations, strategic deals, and improved financials drive pipeline and outlook.MGTX
Q4 202526 Mar 2026 - Late-stage gene therapy programs and strategic partnerships drive global filings and pipeline growth.MGTX
RBC Capital Markets Virtual Ophthalmology Conference26 Mar 2026 - Pivotal programs and riboswitch innovation accelerate cost-effective therapy development.MGTX
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Late-stage genetic medicine programs and the Riboswitch platform promise broad clinical impact.MGTX
Chardan's 8th Annual Genetic Medicines Conference20 Jan 2026 - Transformative gene therapies advance in rare blindness, xerostomia, and Parkinson's, with strong regulatory support.MGTX
RBC Inaugural Virtual Ophthalmology Conference26 Dec 2025 - All 11 children with LCA4 gained vision and developmental benefits after gene therapy.MGTX
Study Update23 Dec 2025